ABERRANT TUMOR METABOLISM ENABLES GR TAKEOVER IN ENZALUTAMIDE-RESISTANT PROSTATE CANCER

$186,215FY2016Department of the ArmyDOD

The Cleveland Clinic Foundation

Investigators